[Effect of the beta-receptor blockers propranolol and talinolol on glucose-orciprenaline induced insulin secretion, glucose tolerance and the behavior of nonesterified free fatty acids in metabolically normal probands].
With the help of a special clinico-pharmacological test arrangement on 5 test persons with healthy metabolism was proved that the oral treatment with the selective beta 1-blocker Cordanum (Talinolol, 0.3 g/die) and with the non-selective beta 1-beta 2-blocker Obsidan (Propranolol, 0.12 g/die) leads to a complete suppression of the insulin secretion which can be additionally mobilised via beta 2-adrenoreceptors in test persons with healthy metabolism. In contrast to Talinolol under the treatment ith the unspecific beta-blocker Propranolol a clear blocking of the beta 2-mediated glycogenolysis which can be evoked with the help of Orciprenalin and of the lipolysis evocable via beta 1-receptors was observed. Due to the more insignificant metabolic side-effects, with regard to an intact energy supply and the maintainance of the physical functional capacity, the selective beta 1-blocker Talinolol is preferred in the long-term therapy of cardiovascular diseases.